Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma

Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma

Abstract Metastatic melanoma can be treated with anti-PD-1 monotherapy or in combination with anti-CTLA-4 or anti-Lag3. However, combination therapy is associated with a high risk of toxicity. Recently, we reported that high plasma soluble CD27 (sCD27) levels reflect the intratumoral interaction of...

Full description

Saved in:
Bibliographic Details
Main Authors: Ikuan Sam, Nadine Benhamouda, Lucie Biard, Laetitia Da Meda, Kristell Desseaux, Barouyr Baroudjan, Ines Nakouri, Marion Renaud, Aurélie Sadoux, Marina Alkatrib, Jean-François Deleuze, Maxime Battistella, Yimin Shen, Matthieu Resche-Rigon, Samia Mourah, Celeste Lebbe, Eric Tartour
Format: Article
Language:English
Published: Springer Nature 2025-03-01
Series:EMBO Molecular Medicine
Subjects:
CD70-CD27 Interaction
Immunotherapy
Melanoma
Predictive Biomarker
Tumor Microenvironment
Online Access:https://doi.org/10.1038/s44321-025-00203-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s44321-025-00203-9

Similar Items